Insights
Search Results
Client Highlights
8.04.25
Firm Advises Prime Medicine on IP Matters Related to $144 Million Public Offering
On August 1, 2025, Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million.
Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the offering. The Wilson Sonsini team included Lou Lieto, Clark Lin, Rachna Ujwal, and Esther Cynn.
Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the offering. The Wilson Sonsini team included Lou Lieto, Clark Lin, Rachna Ujwal, and Esther Cynn.
Client Highlights
6.17.25
Wilson Sonsini Advises Verve Therapeutics on IP Matters Related to Merger with Lilly
On June 17, 2025, Eli Lilly and Company and Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, announced a definitive agreement for Lilly to acquire Verve. Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on IP matters related to the transaction.
Client Highlights
2.22.24
Wilson Sonsini Advises Prime Medicine on IP Matters Related to Upsized Public Offering
On February 20, 2024, Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced the closing of its underwritten upsized public offering of 22,560,001 shares of its common stock. Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the transaction.
The upsized public offering includes the full exercise of the underwriters’ option to purchase 3,360,000 additional shares of its common stock, at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
The Wilson Sonsini team that advised Prime Medicine on IP matters related to the transaction included Lou Lieto, Clark Lin, Rachna Ujwal, Esther Cynn, and David Stanton.
For more information please see Prime Medicine’s press release.
The upsized public offering includes the full exercise of the underwriters’ option to purchase 3,360,000 additional shares of its common stock, at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
The Wilson Sonsini team that advised Prime Medicine on IP matters related to the transaction included Lou Lieto, Clark Lin, Rachna Ujwal, Esther Cynn, and David Stanton.
For more information please see Prime Medicine’s press release.
Client Highlights
2.05.24
Firm Advises Fractyl Health on Patent Matters Related to $110 Million IPO
On February 1, 2024, Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, announced the pricing of its initial public offering of 7,333,333 shares of common stock at a public offering price of $15.00 per share, for total gross proceeds of approximately $110.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Fractyl Health. Wilson Sonsini Goodrich & Rosati advised Fractyl Health on patent matters related to the transaction.
Client Highlights
10.31.23
Firm Advises Verve Therapeutics on IP Matters Related to Expansion of Lilly Relationship
On October 31, 2023, Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced the expansion of its relationship with Eli Lilly and Company (Lilly) to include Verve’s in vivo gene editing programs targeting PCSK9 and ANGPTL3. Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on IP matters related to the transaction.
Client Highlights
9.28.23
Wilson Sonsini Advises Azurity on IP Matters Related to Slayback Pharma Acquisition
On September 27, 2023, Azurity Pharmaceuticals, Inc. announced the closing of its acquisition of Slayback Pharma LLC from existing investors including KKR, a leading global investment firm, and Everstone Capital. Slayback is now a wholly-owned subsidiary of Azurity. Wilson Sonsini Goodrich & Rosati advised Azurity on IP matters related to the transaction.
The acquisition brings together companies with complementary strengths, enhancing Azurity’s ability to realize its purpose of Serving Overlooked Patients. The combined development portfolios are expected to yield a significant number of new medicine launches over the coming years.
The Wilson Sonsini team that advised Azurity on IP matters related to the acquisition includes Clark Lin, Wendy Devine, Ying Chen, Shu Boboila, Xiaoyang Tang, Kevin Tylock, and Johnson Truong.
The acquisition brings together companies with complementary strengths, enhancing Azurity’s ability to realize its purpose of Serving Overlooked Patients. The combined development portfolios are expected to yield a significant number of new medicine launches over the coming years.
The Wilson Sonsini team that advised Azurity on IP matters related to the acquisition includes Clark Lin, Wendy Devine, Ying Chen, Shu Boboila, Xiaoyang Tang, Kevin Tylock, and Johnson Truong.
Client Highlights
6.16.23
Wilson Sonsini Advises Verve on IP Matters Related to Lilly Collaboration
On June 15, 2023, Verve Therapeutics, Inc. announced an exclusive research collaboration with Eli Lilly and Company focused on advancing Verve’s preclinical stage in vivo gene editing program targeting lipoprotein(a) (Lp(a)). Elevated Lp(a) is an established and genetically validated, independent risk factor for atherosclerotic cardiovascular disease (ASCVD), ischemic stroke, thrombosis, and aortic stenosis. Under the terms of the collaboration, Verve will advance the research and development of the Lp(a) program through the completion of Phase 1 clinical development. Lilly will be responsible for subsequent development, manufacturing, and commercialization of the Lp(a) program. Under the terms of the agreement, Verve will receive $60 million consisting of an upfront payment and equity investment. Research program costs through Phase 1 clinical trials will be funded by Lilly. Verve is also eligible to receive up to $465 million in research, development, and commercial milestones, as well as tiered royalties on global net sales. In addition, following the completion of Phase 1 clinical trials, Verve has the right to opt-in to co-fund and share margins globally on the Lp(a) program (in lieu of receipt of milestones and royalties). The closing of the transaction is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act).
Client Highlights
10.20.22
Wilson Sonsini Advises Prime Medicine on Patent Matters Related to $175 Million IPO
On October 19, 2022, Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced the pricing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share. The shares began trading on the Nasdaq Global Market on October 20 under the ticker symbol “PRME.” Wilson Sonsini Goodrich & Rosati is advising Prime Medicine on all patent matters related to the transaction.
The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prime Medicine, are expected to be $175.0 million. In addition, the underwriters have a 30-day option to purchase up to 1,544,117 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prime Medicine, are expected to be $175.0 million. In addition, the underwriters have a 30-day option to purchase up to 1,544,117 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.
Alerts
3.02.22
PTAB Determines Broad Has Priority in Dispute over CRISPR Gene Editing Patents in Eukaryotic Systems
On February 28, 2022, the Patent Trial and Appeal Board (PTAB) issued a decision in Interference No. 106,115, University of California v. Broad Institute, on priority of invention for CRISPR-Cas9 gene editing methods of eukaryotic cells and genomes. The PTAB determined that The Broad Institute, Massachusetts Institute of Technology, and Presidents and Fellows of Harvard College (collectively "Broad") had priority over The Regents of the University of California, University of Vienna, and Emmanuelle Charpentier (collectively "UC"). However, this decision might not conclude the dispute between UC and Broad for the use of CRISPR-Cas9 in eukaryotic systems, as UC likely will appeal the PTAB's decision to the U.S. Court of Appeals for the Federal Circuit. Further, UC's prior patents on CRISPR-Cas9 editing in generic environments are unaffected by this decision.
Press Releases
12.06.21
Wilson Sonsini Elects 23 New Partners
Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, today announced that the firm has elected 23 new partners from its attorney ranks. The promotions will go into effect on February 1, 2022.
Client Highlights
8.25.21
Wilson Sonsini Advises Azurity on Acquisition, Merger with Arbor Pharmaceuticals
On August 24, 2021, Azurity Pharmaceuticals, Inc. and Arbor Pharmaceuticals, Inc. announced they have entered into a definitive agreement in which Azurity will be acquiring Arbor from existing investors including JW Asset Management and KKR. Following the completion of the transaction, which is subject to regulatory approvals, Azurity and Arbor will merge, creating a leading company offering innovative, high-value products to meet the unique needs of patients with underserved conditions. Financial details of the transaction were not disclosed.
Client Highlights
8.20.21
Wilson Sonsini Advises Vida Ventures on Vigil Neuroscience’s $90 Million Series B Financing
On August 18, 2021, Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90 million Series B financing. The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures, and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures. Wilson Sonsini Goodrich & Rosati represented Vida Ventures in the transaction.
The financing will be used to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration. Vigil is developing both a fully human monoclonal antibody, VGL101, and small molecule agonists of triggering receptor on myeloid cells 2 (TREM2), an essential microglia sensor that mediates responses to environmental signals to maintain brain homeostasis.
The financing will be used to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration. Vigil is developing both a fully human monoclonal antibody, VGL101, and small molecule agonists of triggering receptor on myeloid cells 2 (TREM2), an essential microglia sensor that mediates responses to environmental signals to maintain brain homeostasis.